Type 2 diabetes mellitus, its treatment and risk for lymphoma

Fortuny, Joan; Benavente, Yolanda; Bosch, Ramón; García-Villanueva, Mercedes; Sevilla, Alberto Fernández de; Sanjosé, Sílvia de

doi:10.1016/j.ejca.2005.04.032

Cited by 23 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we found a weak inverse relation between insulin treatment and risk of developing NHL, which is consistent with the findings of studies by Fortuny et al 23 and Zhang et al 37 It has been suggested that this effect may be related to continuous stimulation of the immune system by insulin, 23 which is chronically inoculated several times a day. In such a case, longer duration of insulin use should be related to greater protection from NHL, because of stronger immune system stimulation by older insulins of animal origin.…”

Section: Insulin Treatmentsupporting

confidence: 82%

“…It is not clear why such associations were stronger for men than for women. Among previous studies, type 2 diabetes was observed to increase the risk of MM, 23 but not B-CLL. B-CLL is a neoplastic disease characterized by the accumulation of small, mature-appearing lymphocytes in blood, bone marrow, and lymphoid tissues.…”

Section: Lymphoma Subtypesmentioning

confidence: 99%

“…Two of the four cohort studies found an elevated risk of NHL 5,11,21 among diabetic individuals. Four population and hospital-based case-control studies also demonstrated positive associations, [22][23][24][25] while five others reported no or inverse associations. [26][27][28][29] The inconsistency of the findings to date may partly be attributed to differences in study design, lack of information on potential confounders, use of inappropriate comparison populations and ascertainment of cases from cancer or mortality registries.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition

Khan¹,

Gallo²,

Linseisen³

et al. 2008

Haematologica

View full text Add to dashboard Cite

BackgroundNon-Hodgkin's lymphomas are a heterogeneous group of neoplasms arising from the lymphopoietic system including a wide range of subtypes of either B-cell or T-cell lymphomas. The few established risk factors for the development of these neoplasms include viral infections and immunological abnormalities, but their etiology remains largely unknown. Evidence suggests that certain medical conditions may be linked, through immunosuppression, to the risk of nonHodgkin's lymphoma. Multiple myeloma is a neoplasm of plasma cells that accounts for approximately 15% of lymphopoietic cancers. Increases in the incidence of non-Hodgkin's lymphoma and multiple myeloma in the past implicate environmental factors as potential causal agents.

show abstract

Section: Insulin Treatmentsupporting

confidence: 82%

Section: Lymphoma Subtypesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition

Khan¹,

Gallo²,

Linseisen³

et al. 2008

Haematologica

View full text Add to dashboard Cite

show abstract

“…34 It would be of interest to investigate a possible link between hyperinsulinemia-related markers and clinical and survival outcome in patients with MM. In particular, an increased risk for MM is found in patients with type II diabetes 35 as that was found for risk of overall cancers. 36 The current observation that insulin is a potent myeloma cell growth factor, signaling through hybrid-Rs, is of importance in several ways: (1) for the development of therapies targeting the IGF axis in patients with MM.…”

Section: Discussionmentioning

confidence: 86%

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation

et al. 2010

View full text Add to dashboard Cite

“…We identified 10 manuscripts reporting data from 11 case-control studies published between 1988 and 2007 (Table 2) (7,(21)(22)(23)(24)(25)(26)(27)(28)(29). A total of 382 cases of NHL were reported among 4,844 patients with diabetes, whereas a total of 7,974 cases of NHL were reported among 86,660 control subjects without diabetes.…”

Section: Characteristics Of Case-control Studiesmentioning

confidence: 99%

Diabetes and Risk of Non-Hodgkin's Lymphoma

2008

View full text Add to dashboard Cite

OBJECTIVE -To examine the epidemiologic association between diabetes and risk of nonHodgkin's lymphoma (NHL).RESEARCH DESIGN AND METHODS -We searched MEDLINE for observational studies on the association between diabetes and NHL in adults using the keywords "diabetes" and "lymphoma." Prospective cohort studies that reported relative risks or standardized incidence ratios and case-control studies that reported odds ratios with 95% CIs were included. A randomeffects model was used to combine results from the individual studies.RESULTS -A total of 15 manuscripts (reporting data from 5 prospective cohort and 11 case-control studies) met the inclusion criteria. Combining data from all studies, the risk ratio (RR) of developing NHL in patients with diabetes was 1.19 (95% CI 1.04 -1.35). Based on prospective studies, patients with diabetes had an RR of developing NHL of 1.41 (1.07-1.88), without heterogeneity among studies (I 2 ϭ 34.3%; P Ͼ 0.10). Based on case-control studies, patients with diabetes had an RR of 1.12 (95% CI 0.95-1.31) of developing NHL compared with people without diabetes, with some heterogeneity among studies (I 2 ϭ 36.28%; P ϭ 0.09).CONCLUSIONS -Diabetes is associated with a moderately increased risk of NHL, which is consistent with other reported associations between diabetes and malignancies. Future studies should focus on elucidating potential pathophysiologic links between diabetes and NHL.

show abstract

Type 2 diabetes mellitus, its treatment and risk for lymphoma

Cited by 23 publications

References 29 publications

Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition

Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation

Diabetes and Risk of Non-Hodgkin's Lymphoma

Contact Info

Product

Resources

About